Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 10 Issue 11, November 2010

From The Editors

Top of page ⤴

Research Highlight

  • Spatial and temporal regulation of TLR9 signalling determines response pathway.

    • Kirsty Minton
    Research Highlight
  • The anti-apoptotic protein MCL1 is crucial for germinal centre B cell responses.

    • Yvonne Bordon
    Research Highlight
  • Activation of BATF by PD1 contributes to T cell exhaustion in HIV infection.

    • Olive Leavy
    Research Highlight
  • Islet amyloid polypeptide (IAPP) activates the NLRP3 inflammasome for IL-1β production.

    • Olive Leavy
    Research Highlight
  • Inflammatory responses generate endogenous TLR2 ligands that promote angiogenesis.

    • Yvonne Bordon
    Research Highlight
Top of page ⤴

Structure Watch

Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Research Highlight

Top of page ⤴

Review Article

  • The mechanisms by which local antigen-presenting cells, such as myeloid and plasmacytoid dendritic cells, liver sinusoidal endothelial cells, Kupffer cells and hepatocytes, mediate tolerance to antigens metabolized in the liver are described here. These insights into hepatic tolerance may be harnessed in the clinic for the treatment of various diseases.

    • Angus W. Thomson
    • Percy A. Knolle
    Review Article
  • Natural IgM has many roles in the immune system, from protection against infection to regulating autoimmunity. The authors discuss the pleiotropic properties of natural IgM, and the implications for B cell-targeted therapy.

    • Michael R. Ehrenstein
    • Clare A. Notley
    Review Article
Top of page ⤴

Timeline

  • The ITN was founded in 1999 with the goal of achieving “... a robust state of immune tolerance in the absence of ongoing immunotherapy while maintaining a competent immune system”. What are the challenges that have been met along the way and the lessons learnt for future translational research?

    • Jeffrey A. Bluestone
    • Hugh Auchincloss
    • Laurence A. Turka
    Timeline
Top of page ⤴

Search

Quick links